Nanjing Vishee Medical Technology Co., Ltd

Equities

688580

CNE1000041Q0

Advanced Medical Equipment & Technology

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
43.3 CNY -5.95% Intraday chart for Nanjing Vishee Medical Technology Co., Ltd -0.14% -32.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nanjing Vishee Medical Technology Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Nanjing Vishee Medical Technology Co., Ltd's Equity Buyback Plan announced on November 10, 2023. CI
Nanjing Vishee Medical Technology Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Nanjing Vishee Medical Technology Co., Ltd's Equity Buyback Plan announced on November 10, 2023. CI
Vishee Medical Registers Medical Device MT
Nanjing Vishee Medical Technology Co., Ltd announces an Equity Buyback for CNY 40 million worth of its shares. CI
Nanjing Vishee Medical Technology Co., Ltd authorizes a Buyback Plan. CI
Nanjing Vishee Medical Technology Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Nanjing Vishee Medical Technology Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Certain A Shares of Nanjing Vishee Medical Technology Co., Ltd are subject to a Lock-Up Agreement Ending on 21-JUL-2023. CI
Nanjing Vishee Medical Technology Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tranche Update on Nanjing Vishee Medical Technology Co., Ltd's Equity Buyback Plan announced on April 12, 2022. CI
Nanjing Vishee Medical Technology Co., Ltd's Equity Buyback announced on April 12, 2022, has expired with 401,448 shares, representing 0.59% for CNY 20.01 million. CI
Nanjing Vishee Medical Technology Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Nanjing Vishee Medical Technology Co., Ltd's Equity Buyback Plan announced on April 12, 2022. CI
Nanjing Vishee Medical to Acquire 70% of Kerida Laser for $8 Million MT
Nanjing Vishee Medical Technology Co., Ltd agreed to acquire a 70% stake in Hefei Hans Curestar Laser Device Co., Ltd. from Wang Bizhan, Huang Heng, Yang Aichun and Xu Qingfen for CNY 58.8 million. CI
Nanjing Vishee Medical Technology Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tranche Update on Nanjing Vishee Medical Technology Co., Ltd's Equity Buyback Plan announced on April 12, 2022. CI
Nanjing Vishee Medical Technology Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Nanjing Vishee Research and Innovation Information Technology Co., Ltd announced that it expects to receive CNY 74.86 million in funding from Nanjing Vishee Medical Technology Co., Ltd CI
Tranche Update on Nanjing Vishee Medical Technology Co., Ltd's Equity Buyback Plan announced on April 12, 2022. CI
Nanjing Vishee Medical Technology Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Nanjing Vishee Medical Technology Co., Ltd announces an Equity Buyback for CNY 40 million worth of its shares. CI
Nanjing Vishee Medical Technology Co., Ltd authorizes a Buyback Plan. CI
Chart Nanjing Vishee Medical Technology Co., Ltd
More charts
Nanjing Vishee Medical Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of rehabilitation medical equipment and products. The Company’s products are mainly electrical stimulation, magnetic stimulation, electrophysiological equipment, consumables and accessories and other rehabilitation medical equipment and products, such as pelvic floor muscle recovery equipment, transcranial magnetic stimulator, neonatal electroencephalography measuring instrument, rectal electrode, micro current stimulator and others. The Company mainly conducts its businesses within the domestic market.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
43.3 CNY
Average target price
77 CNY
Spread / Average Target
+77.83%
Consensus

Annual profits - Rate of surprise